Dr Reddy’s dips 8% after receiving Complete Response Letter from USFDA; Citi cuts target
Global brokerage Citi slashed price target to Rs 2,375 from Rs 2,540 per share, citing likely more delay in female contraceptive drug launch after fresh Complete Response Letter from US FDA.